V
VISA Inc.
stock NYSE

Check out FLT.V. Canadian Drone company. This stock just got conditional TSX up listing approval. Stock is set to be first choice for more NATO contracts and Arctic Sovereignty contracts. It’s now up 50% over the last few weeks and up 335% this last year.

For awareness, new Tomahawk cruise missile (specifically the Block V variant) costs approximately $1.3 million to $2.5 million per unit, according to 2026 U.S. budget data and recent procurement reports.
Would have been a lot of food (or housing or medical care, etc).

Yay I’m green but, Mehnnnn today’s gonna be the inverse huh… it’s gonna be the upside down V 😔

"just do a V bro"
brutal 💔🥀

who's ready for another shrek dick V shortly after open?

V insightful, and great analysis!
Let me try and bridge it to the mgmt guidance (at least as I see it).
Firstly, the 9000 procedures is a 2023 number, they’ve stated they model a 1.8% CAGR on that. So it we take peak sales in 2028/29, we get c.10k procedures.
Now to your point of share and if it’s just relevant for AML/MDS. The comprehensive European data and Robin study shows that share scaling to +30% on all procedures. Key to understand is that there is significant off-label usage. If a frail patient with Myelofibrosis or ALL cannot tolerate the extreme toxicity of busulfan, the physician will naturally pivot to treosulfan (off label in US oncology, especially this subsegment, is highly legitimised).
Personally, I can get behind a 30%, perhaps even higher share of total procedures. Do you have any reservations about it & why?
With that in mind, you’re probably still left $30mn short when updating your model on peak-sales.
The bridge comes from 1) adjusting for realistic US BSA demographics, 2) vial wastage, 3) some price inflation for the top end guidance. Whether or not this is aggressive or conservative is open to interpretation. Management would probably tell us we must pivot from theoretical clinical requirements to the commercial reality of US hospital billing - and they do, to a degree, have a fair point.
Then, You’re right ntap doesn’t go to Medexus, think of it merely as an adoption accelerator. What we want to see is fast uptake across transplantation centres and formulary inclusion. With a slight lag, that should feed into adoption and entrenchment as standard-of-care, as it has in Europe.
As you mention, even if we’re overly conservative on peak sales estimates and take bottom end procedural share guidance, you get a decent underwrite at current valuation. V. Rare to have a product with such strong clinical data and well understood by physicians already, so, imo, there’s some decent right-tail skew one buys at around C$3/share.
How do you think about it?

that V got un-Ved real quick

AVAVAV..., today is V, so tomorrow should be a A

So no mo V's huh. Maybe just half W's

Who doesn't like a Korean V

Tomorrow is either straight up or straight down. Surely we don't do another V 3 days in a row

Korean Kospi down 12%, circuit breaking, and now V'ing into close down only 7%

KO and V is good

The V crowd is gonna get pummeled tomorrow

V shape recovery?

When do you think the V will be tomorrow? Morning or afternoon?

South Korea 100% relies on foreign oil and the war is blocking a trade route for them to import oils. I think the market over-reacted because KOSPI was going up so rapidly for so long. If the Iran war ends soon, this drop will be easily recoverable because South Korea always holds oil supplies in advance to last a couple of months. Historically, South Korea recovers immediately with a V shape curve when the interruption to oil is short term. If the war lasts long enough, then the drop will take a lot longer time to recover. That's what happened around COVID. It took them 2-3 years to recover. I also hold EWY/KORU mix. I do not doubt on their fundamentals. It would be other logistics complicated by this war if it doesn't end soon enough..

Thoughts...
If you had to pick one
SGQ V ARU
Who ya going with

It’s gonna V within 0.5% of today’s close tomorrow. And then probably again on Thursday. Friday will be a face ripper up or down.

* **Coke** \- Their PE is too high for single digit projected growth. Concerns about sugar/carbs are real and sugar taxes are becoming popular in countries. Coke is also in a low dollar bubble...when the dollar is cheap their earnings look better than normal because third world countries can finally afford their crap.
* **BRK** \- Very overvalued. Investors have been disappointed in its returns this year...but it will continue to fall as the core investments are not good and are way overvalued.
* **MSFT** \- Likely your best stock. Although likely a bit overpriced at a forward pe of 35x. MSFT is going to encounter constraints that will limit growth. And their partnership with OpenAI is not trustworthy.
* **V** \- I was a long time investor...held since their IPO year but sold last November. Their entire business model is getting upended...and they face existensial risk. This is your most dangerous stock. I wrote an essay on Visa here: [https://www.reddit.com/r/ValueInvesting/comments/1p0tk5q/comment/npn1ot0/](https://www.reddit.com/r/ValueInvesting/comments/1p0tk5q/comment/npn1ot0/)